185416-31-3

Basic information

• Product Name: Methanone, [2-(2,4-dimethoxyphenyl)-6-methoxybenzo[b]thien-3-yl][4-[2-(1-piperidin yl)ethoxy]phenyl]-
• CAS NO: 185416-31-3
• Molecular Formula: C31H33NO5S
• Molecular Weight: 531.673
• Mol File: 185416-31-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Methanone, [2-(2,4-dimethoxyphenyl)-6-methoxybenzo[b]thien-3-yl][4-[2-(1-piperidin yl)ethoxy]phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Methanone, [2-(2,4-dimethoxyphenyl)-6-methoxybenzo[b]thien-3-yl][4-[2-(1-piperidin yl)ethoxy]phenyl]-(185416-31-3)
• EPA Substance Registry System: Methanone, [2-(2,4-dimethoxyphenyl)-6-methoxybenzo[b]thien-3-yl][4-[2-(1-piperidin yl)ethoxy]phenyl]-(185416-31-3)

Safety Data

• Hazardous Substances Data: 185416-31-3(Hazardous Substances Data)

Upstream product

• 17715-69-4 1-Bromo-2,4-dimethoxybenzene 
• 138109-49-6 2,4-dimethoxyphenylmagnesium bromide 
• 111359-29-6 6-methoxy-N,N-dimethylbenzo[b]thiophen-2-amine 
• 165742-76-7 [2-dimethylamino-6-methoxybenzothien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone 

Relevant articles and documents

Benzo [B] thiophene compounds, and compositions for treating bone loss, and hyperlipidemia

The invention provides benzo[b]thiophene compounds, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pat

Structure-activity relationships of selective estrogen receptor modulators: Modifications to the 2-arylbenzothiophene core of raloxifene

The 2-arylbenzothiophene raloxifene, 1, is a selective estrogen receptor modulator which is currently under clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. A series of raloxifene analogs which contain modifications to the 2-arylbenzothiophene core have been prepared and evaluated for the ability to bind to the estrogen receptor and inhibit MCF-7 breast cancer cell proliferation in vitro. Their ability to function as tissue-selective estrogen agonists in vivo has been assayed in a short-term, ovariectomized (OVX) rat model with end points of serum cholesterol lowering, uterine weight gain, and uterine eosinophil peroxidase activity. These studies have demonstrated that (1) the 6-hydroxy and, to a lesser extent, the 4'-hydroxy substituents of raloxifene are important for receptor binding and in vitro activity, (2) small, highly electronegative 4'- substituents such as hydroxy, fluoro, and chloro are preferred both in vitro and in vivo, (3) increased steric bulk at the 4'-position leads to increased uterine stimulation in vivo, and (4) additional substitution of the 2-aryl moiety is tolerated while additional substitution at the 4-, 5-, or 7- position of the benzothiophene results in reduced biological activity. In addition, compounds in which the 2-aryl group is replaced by alkyl, cycloalkyl, and naphthyl substituents maintain a profile of in vitro and in vivo biological activity qualitatively similar to that of raloxifene. Several novel structural variants including 2-cyclohexyl, 2-naphthyl, and 6- carbomethoxy analogs also demonstrated efficacy in preventing bone loss in a chronic OVX rat model of postmenopausal osteopenia, at doses of 0.1-10 mg/kg.